New Preclinical Data Presented at the 2021 American Society of Genetic & Cell Therapy Annual Meeting Highlights Precision BioSciences’ ARCUS In Vivo Genome Editing
Retrieved on:
Tuesday, May 11, 2021
Health, Genetics, Clinical trials, Research, Science, Pharmaceutical, Biotechnology, Chlamydomonadales, Biotechnology, Branches of biology, Molecular biology, Restriction enzymes, Life sciences, Chlamydomonas reinhardtii, Hydrogen production, Biology, I-CreI, Arcus, Chlamydomonas, ARCUS, Precision BioSciences, Inc., ARCUS, PRECISION BIOSCIENCES, INC.
ARCUS is based on a naturally occurring genome editing enzyme, I-CreI that evolved in the algae Chlamydomonas reinhardtii to make highly specific cuts in cellular DNA.
Key Points:
- ARCUS is based on a naturally occurring genome editing enzyme, I-CreI that evolved in the algae Chlamydomonas reinhardtii to make highly specific cuts in cellular DNA.
- ARCUS is a highly specific and versatile genome editing platform that was designed with therapeutic safety, delivery, and control in mind.
- Using ARCUS, the Company\xe2\x80\x99s pipeline consists of multiple \xe2\x80\x9coff-the-shelf\xe2\x80\x9d CAR T immunotherapy clinical candidates and several in vivo gene correction therapy candidates to cure genetic and infectious diseases where no adequate treatments exist.
- For more information about Precision BioSciences, please visit www.precisionbiosciences.com.\nThis press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.